Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Peyronie's disease (PD) is a fibrotic disorder of the penile tunica albuginea, characterised by the formation of a localised fibrous plaque that can lead to deformity and erectile dysfunction. Nonsurgical therapeutic options for PD are limited in efficacy and safety. Myofibroblasts are key cells in the pathogenesis of PD, and inhibition of myofibroblast transformation has been suggested as a therapeutic option. OBJECTIVE: To identify potential drugs using a novel phenotypic assay and then to test them using in vitro and in vivo models of PD. DESIGN, SETTING, AND PARTICIPANTS: We have developed and validated a phenotypic screening assay that measures myofibroblast transformation, by which we tested 21 compounds that were suggested to be efficacious in treating PD. The successful hits from this assay were further tested using in vitro and in vivo models of PD. RESULTS AND LIMITATIONS: The new assay was able to detect transforming growth factor-β1-induced myofibroblast transformation. Using this assay, phosphodiesterase type 5 inhibitors (PDE5i) and selective oestrogen receptor modulators (SERMs) were identified to significantly inhibit myofibroblast transformation. A PDE5i (vardenafil) and an SERM (tamoxifen) inhibited myofibroblast transformation, collagen gel contraction, and extracellular matrix production in a synergistic fashion. In a rat model of PD, the antifibrotic effect of the combination of vardenafil and tamoxifen was greater than that of each drug alone. This study is limited by not providing a molecular mechanism for the proposed synergy. CONCLUSIONS: This is the first demonstration of a synergistic activity between a PDE5i and an SERM discovered through a phenotypic screening approach. Future clinical trials using a combination of these drugs should be considered during the active phase of PD, given the early evidence of benefit in both in vitro and in vivo models. PATIENT SUMMARY: This report suggests that the combination of a phosphodiesterase type 5 inhibitor and a selective oestrogen receptor modulator may be efficacious in treating Peyronie's disease in its active phase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
Cytokine mediated tissue fibrosis
Borthwick, L. A., Wynn, T. A., & Fisher, A. J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.09.014 · Cited by 375
The Chronology of Depression and Distress in Men with Peyronie's Disease
Nelson, C. J., Diblasio, C., Kendirci, M., Hellstrom, W., Guhring, P., & Mulhall, J. P. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.00895.x · Cited by 255
JIANG, H.-S., ZHU, L.-L., ZHANG, Z., CHEN, H., CHEN, Y., & DAI, Y.-T. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2288 · Cited by 50
Deformity stabilization and improvement in men with untreated Peyronie's disease
Berookhim, B. M., Choi, J., Alex, B., & Mulhall, J. P. (2014) · BJU International · doi:10.1111/bju.12346 · Cited by 48
Cited by
The Natural History of Peyronie’s Disease
Di Maida, F., Cito, G., Lambertini, L., Valastro, F., Morelli, G., Mari, A., Carini, M., Minervini, A., & Cocci, A. (2021) · The World Journal of Men's Health · doi:10.5534/wjmh.200065 · Cited by 59
Milenkovic, U., Boeckx, B., Lambrechts, D., Janky, R., Hatzichristodoulou, G., van Renterghem, K., Gevaert, T., Cellek, S., Bivalacqua, T. J., De Ridder, D., et al. (2022) · European Urology Focus · doi:10.1016/j.euf.2021.04.012 · Cited by 14
Self-citationConservative Therapy for Peyronie’s Disease: a Contemporary Review of the Literature
Yousif, A., Natale, C., & Hellstrom, W. J. G. (2021) · Current Urology Reports · doi:10.1007/s11934-020-01024-8 · Cited by 12
Metadata
- Authors
- Ilg, M. M., Mateus, M., Stebbeds, W. J., Milenkovic, U., Christopher, N., Muneer, A., Albersen, M., Ralph, D. J., & Cellek, S.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 75
- Issue
- 2
- Pages
- 329-340
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2895852226
- Cited by
- 48
- References
- 5
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models. https://app.cochat.ai/papers/10.1016/j.eururo.2018.10.014
- The paper
- Ilg, M. M., Mateus, M., Stebbeds, W. J., Milenkovic, U., Christopher, N., Muneer, A., Albersen, M., Ralph, D. J., & Cellek, S. (2019). Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models. European Urology. https://doi.org/10.1016/j.eururo.2018.10.014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.